Kenneth W. Mahaffey, MD

Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Inhibitors with Percutaneous Coronary Intervention in Acute <br />
Coronary S

08/01/2008

Rahul A. Shimpi , MD;

Kenneth W. Mahaffey , MD;

James E. Tcheng , MD;

Profound advancements in the management of acute coronary syndromes (ACS) have been realized in recent years. Initial medical therapy for non-ST segment elevation ACS has evolved to include the use of the combined treatment modalities of...

Profound advancements in the...

08/01/2008

Journal of Invasive Cardiology

The Anticoagulant Therapy with Bivalirudin to Assist in the <br />
Performance of Percutaneous Coronary Intervention in Patients with

08/01/2008

Mark A. Turco , MD, FACC;

Yoseph Shalev , MD;

Peter Ver Lee , MD;

A. Ralph Rodriguez , MD;

E. Magnus Ohman , MD;

Robert A. Harrington , MD;

Robert M. Califf , MD;

Jay H. Traverse , MD;

Kenneth W. Mahaffey , MD;

Bruce E. Lewis , MD;

Nancy M. Wildermann , BA;

Scott D. Berkowitz , MD;

Renee M. Oliverio , RN;

Heparin-induced thrombocytopenia (HIT) is infrequent and often goes unrecognized. It occurs in ~1% to 5% of the patients given unfractionated heparin,1 about 25–50% of whom will develop HIT with thrombotic syndrome (HITTS).2 Morbidity and...

Heparin-induced thrombocytopenia...

08/01/2008

Journal of Invasive Cardiology